Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts
出版年份 2014 全文链接
标题
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts
作者
关键词
Cervical Intraepithelial Neoplasia, Vaccine Efficacy, Genital Wart, Vaccine Adverse Event Reporting System, Vulvar Intraepithelial Neoplasia
出版物
DRUGS
Volume 74, Issue 11, Pages 1253-1283
出版商
Springer Nature
发表日期
2014-07-14
DOI
10.1007/s40265-014-0255-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil
- (2015) Lucija Tomljenovic et al. JOURNAL OF LAW MEDICINE & ETHICS
- Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling
- (2014) Yvonne Deleré et al. BMC INFECTIOUS DISEASES
- Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women
- (2014) Joaquin Luna et al. PLoS One
- Adverse events following immunization in Ontario's female school-based HPV program
- (2014) Tara Harris et al. VACCINE
- Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities
- (2014) Sara L. Bissett et al. VACCINE
- Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia
- (2014) E. Crowe et al. BMJ-British Medical Journal
- Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis
- (2014) Xavier Bresse et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003–2010: Potential Impact of Human Papillomavirus Vaccination
- (2013) Elaine W. Flagg et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Human Papilloma Virus Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants
- (2013) Serena Colafrancesco et al. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
- (2013) Dorota M Gertig et al. BMC Medicine
- Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years
- (2013) Hiroyuki Yoshikawa et al. CANCER SCIENCE
- Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women
- (2013) Jessica A. Kahn et al. CLINICAL INFECTIOUS DISEASES
- Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)?
- (2013) Woo Dae Kang et al. GYNECOLOGIC ONCOLOGY
- Immunogenicity and Tolerability to Human Papillomavirus-like Particle Vaccine in Girls and Young Women with Inflammatory Bowel Disease
- (2013) Denise L. Jacobson et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women
- (2013) Simon R. M. Dobson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects
- (2013) Carlo Perricone et al. JOURNAL OF AUTOIMMUNITY
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010
- (2013) Lauri E. Markowitz et al. JOURNAL OF INFECTIOUS DISEASES
- Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
- (2013) Amy Leval et al. JNCI-Journal of the National Cancer Institute
- Human papillomavirus vaccine in boys: background rates of potential adverse events
- (2013) Hazel J Clothier et al. MEDICAL JOURNAL OF AUSTRALIA
- A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls
- (2013) Eve Draper et al. PLoS One
- Near Elimination of Genital Warts in Australia Predicted With Extension of Human Papillomavirus Vaccination to Males
- (2013) Igor A. Korostil et al. SEXUALLY TRANSMITTED DISEASES
- HPV Vaccine Works against Nine Viral Types
- (2013) Cancer Discovery
- Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study
- (2013) L. Arnheim-Dahlstrom et al. BMJ-British Medical Journal
- Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data
- (2013) H. Ali et al. BMJ-British Medical Journal
- Guillain–Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States
- (2013) Rohit P Ojha et al. Human Vaccines & Immunotherapeutics
- Evidence of Human Papillomavirus Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–2010
- (2012) Heidi M. Bauer et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study
- (2012) Chi Chiu Mok et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females
- (2012) Nicola P. Klein et al. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
- Assessment of eight HPV vaccination programs implemented in lowest income countries
- (2012) Joël Ladner et al. BMC PUBLIC HEALTH
- Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme
- (2012) Agnes Binagwaho et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women
- (2012) Marek Petráš et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Clinical Trial Experience With Prophylactic Human Papillomavirus 6/11/16/18 Vaccine in Young Black Women
- (2012) Liana R. Clark et al. JOURNAL OF ADOLESCENT HEALTH
- Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil®
- (2012) Sin Hang Lee JOURNAL OF INORGANIC BIOCHEMISTRY
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- (2012) Talía Malagón et al. LANCET INFECTIOUS DISEASES
- Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases
- (2012) Giampiero Favato et al. MEDICAL CARE
- Changes in Incidence of Anogenital Warts Diagnoses After the Introduction of Human Papillomavirus Vaccination in Germany—An Ecologic Study
- (2012) Rafael T. Mikolajczyk et al. SEXUALLY TRANSMITTED DISEASES
- Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females
- (2012) Rongcheng Li et al. VACCINE
- Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries
- (2012) Karen Canfell et al. VACCINE
- Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan
- (2012) Nadia Demarteau et al. VALUE IN HEALTH
- Evaluation of the HPV 18 antibody response in Gardasil®vaccinees after 48 mo using a pseudovirion neutralization assay
- (2012) Christine Roberts et al. Human Vaccines & Immunotherapeutics
- End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
- (2011) X Castellsagué et al. BRITISH JOURNAL OF CANCER
- Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old
- (2011) Richard J. Hillman et al. Clinical and Vaccine Immunology
- Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults
- (2011) Edson D. Moreira et al. Human vaccines & immunotherapeutics
- The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay
- (2011) Darron R. Brown et al. Human vaccines & immunotherapeutics
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine
- (2011) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
- (2011) C. Chao et al. JOURNAL OF INTERNAL MEDICINE
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
- (2011) Julia ML Brotherton et al. LANCET
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
- (2011) Anna R. Giuliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
- (2011) Joel M. Palefsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost-effectiveness of male HPV vaccination in the United States
- (2011) Harrell W. Chesson et al. VACCINE
- Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink
- (2011) Julianne Gee et al. VACCINE
- Human Papillomavirus Vaccines
- (2010) Suzanne M. Garland et al. DRUGS
- Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
- (2010) Sven-Eric Olsson et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
- (2010) Jens Olsen et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
- (2010) Myron J Levin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men
- (2010) Timothy Wilkin et al. JOURNAL OF INFECTIOUS DISEASES
- Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis
- (2010) Jane J Kim LANCET INFECTIOUS DISEASES
- Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
- (2010) Basil Donovan et al. LANCET INFECTIOUS DISEASES
- Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine
- (2010) Stan L. Block et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel
- (2010) K. S. Reisinger et al. PEDIATRICS
- Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines
- (2010) A. Arguedas et al. VACCINE
- Impact of vaccinating boys and men against HPV in the United States
- (2010) Elamin H. Elbasha et al. VACCINE
- A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®
- (2010) Paolo Bonanni et al. VACCINE
- The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
- (2010) Erik J. Dasbach et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico
- (2009) Luz Myriam Reynales-Shigematsu et al. ARCHIVES OF MEDICAL RESEARCH
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
- (2009) S. K. Kjaer et al. Cancer Prevention Research
- A cost–utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme
- (2009) Anne Dee et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
- Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
- (2009) Barbara A. Slade JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine
- (2009) Suzanne M. Garland et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
- (2009) Cosette M. Wheeler et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24
- (2009) S Majewski et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
- (2009) Nubia Muñoz et al. LANCET
- Pregnancy Outcomes From the Pregnancy Registry of a Human Papillomavirus Type6/11/16/18 Vaccine
- (2009) Adrian Dana et al. OBSTETRICS AND GYNECOLOGY
- Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine
- (2009) Suzanne M. Garland et al. OBSTETRICS AND GYNECOLOGY
- Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
- (2009) Lieven Annemans et al. PHARMACOECONOMICS
- Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia
- (2009) Mira L. Katz et al. VACCINE
- Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria
- (2009) Ingrid Zechmeister et al. VACCINE
- The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
- (2008) EJ Dasbach et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Anaphylaxis following quadrivalent human papillomavirus vaccination
- (2008) J. M.L. Brotherton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
- (2008) Thomas D. Szucs et al. CURRENT MEDICAL RESEARCH AND OPINION
- Health and economic impact associated with a quadrivalent HPV vaccine in Italy
- (2008) F.S. Mennini et al. GYNECOLOGIC ONCOLOGY
- Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France
- (2008) Christine Bergeron et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Health and Economic Implications of HPV Vaccination in the United States
- (2008) Jane J. Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
- (2008) Elmar A. Joura et al. VACCINE
- Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
- (2008) Erik J Dasbach et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
- (2007) Cosette M. Wheeler et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now